ClinicalTrials.gg

Program

Low dose MOPEVAC-Las vaccine

Also written as “Intermediate dose MOPEVAC-Las vaccine” and “High dose MOPEVAC-Las vaccine”.

Its studies are led by Institut Pasteur.

Furthest: phase 1, since Sep 16, 20261 company-led study, 1 open or runningNext primary completion: Apr 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Institut Pasteur11 open or runningphase 1since Sep 16, 2026Sep 16, 2026Apr 2028phase 1 · NCT07833436

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 16, 2026First study: phase 1 study in Lassa FeverFirst studyNCT07833436 · 72 planned · France

Ahead

  1. Apr 2028Primary completion: phase 1 study in Lassa FeverNCT07833436

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Low dose MOPEVAC-Las vaccine”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07833436Lassa Fever · France1RecruitingApr 202872

How it is read

Names in the registry

  • “Low dose MOPEVAC-Las vaccine”, 1 entry
  • “Intermediate dose MOPEVAC-Las vaccine”, 1 entry
  • “High dose MOPEVAC-Las vaccine”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.